bupropion ER / Generic mfg. - LARVOL DELTA

Sex-specific treatment effects with adjunctive antidepressant maintenance treatment in bipolar-I depression (WFSBP 2026) - " This was a post-hoc analysis of an RCT of adjunctive escitalopram or bupropion XL in patients with BD-I who had recently remitted from a depressive episode. In this post-hoc analysis, adjunctive antidepressant maintenance treatment for 52 weeks significantly prolonged the time to any mood episode in women as compared to men with BD-I. These sex-specific effects highlight the potential value of personalized, sex-informed treatment approaches and warrant confirmation in larger prospective trials."

Clinical • Bipolar Disorder • CNS Disorders • Depression • Mood Disorders • Psychiatry

Case Report: Oral semaglutide-associated depression in a patient with type 2 diabetes mellitus: a dose-dependent recurrence confirmed on rechallenge and managed with vortioxetine-bupropion combination therapy. (PubMed, Front Psychiatry) - "Vortioxetine 10 mg combined with bupropion XL 150 mg produced remission within 4 weeks (PHQ-9: 6). A Naranjo score of 7 puts the relationship in the probable range, though that reading is held back by the usual limits of a single case and by an incomplete washout before rechallenge. The step from 3 to 7 mg may be a point of raised psychiatric risk in vulnerable patients, and watching mood during titration looks like a sensible precaution."

Journal • CNS Disorders • Depression • Diabetes • Major Depressive Disorder • Metabolic Disorders • Mood Disorders • Psychiatry • Suicidal Ideation • Type 2 Diabetes Mellitus

Projected budget impact of pharmacotherapy scenarios for obesity and related conditions in Peru: A national survey analysis of 76,819 participants. (PubMed, Obes Pillars) - "Liraglutide 3.0 mg and semaglutide 2.4 mg represent high-cost non-governmental retail scenarios rather than expected institutional procurement estimates. Extended-release naltrexone/bupropion provides a lower-cost non-GLP-1 comparator,and extended-release phentermine/topiramate was analyzed only as an exploratory supplementary comparator."

HEOR • Journal • Genetic Disorders • Obesity

Bupropion for the Prevention of Postpartum Smoking Relapse (clinicaltrials.gov) - P4 | N=161 | Completed | Sponsor: University of Minnesota | Recruiting ➔ Completed

Trial completion

Dose-related Manic Switch with Psychotic Features Following Bupropion Titration: A Case Report. (PubMed, Clin Psychopharmacol Neurosci) - "In this report, we present a male patient with bipolar I disorder who developed a psychotic manic episode following an increase in bupropion XL dose from 150 mg to 300 mg/day while receiving lithium treatment. This case highlights that, despite its reputation as a relatively safe antidepressant in bipolar depression, bupropion may precipitate dose-related manic and psychotic switches. Based on the clinical findings observed in this patient, cautious dose titration beyond 150 mg/day may be considered in individuals with bipolar disorder with psychotic features, with particular attention to close clinical monitoring following any dose escalation."

Journal • Bipolar Disorder • CNS Disorders • Depression • Mood Disorders • Psychiatry

Initiating dextromethorphan-bupropion extended release in patients with major depressive disorder: Delphi panel expert consensus recommendations. (PubMed, Curr Med Res Opin) - "To establish consensus recommendations for initiating dextromethorphan-bupropion extended release (45 mg/105 mg) (AUVELITY) for the treatment of major depressive disorder (MDD) in adults. Key consensus recommendations (abbreviated here) included: (1) dextromethorphan-bupropion is recommended as a first-line treatment for MDD, including with co-occurring symptoms of anxiety; (2) HCPs should individualize treatment decisions that prioritize safety considerations noted in the Prescribing Information; (3) dextromethorphan-bupropion is recommended for patients with inadequate response, residual symptoms, and/or intolerable side effects associated with prior MDD treatment(s); (4) when switching from (or adding to current) medication, the potential for a drug interaction should be considered, consistent with the dextromethorphan-bupropion label; and (5) switching from ketamine or esketamine should be done with caution, and with an awareness of the short-to-intermediate..."

Journal • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder (clinicaltrials.gov) - P3 | N=360 | Active, not recruiting | Sponsor: National Institute on Drug Abuse (NIDA) | Recruiting ➔ Active, not recruiting

Enrollment closed

Development of a MHBC Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients (clinicaltrials.gov) - P1 | N=20 | Not yet recruiting | Sponsor: Medical University of South Carolina | Initiation date: Mar 2026 ➔ Sep 2026

Trial initiation date • Genetic Disorders • Obesity • Tobacco Cessation

Design of INFORMUS, a pragmatic, randomized, double-blind, placebo-controlled study of cardiovascular outcomes with the extended-release, fixed-dose combination of naltrexone and bupropion. (PubMed, Obes Pillars) - P3, P4 | "Approximately 8600 participants will be randomized 1:1 to NB-ER (final dose of 32 mg naltrexone ER, 360 mg bupropion ER) or placebo...The incidence of other adverse events will also be monitored throughout the trial. Findings from INFORMUS will further characterize CV risk associated with NB-ER in adults with obesity or overweight at increased CV risk."

Clinical • Journal • Cardiovascular • Congestive Heart Failure • Genetic Disorders • Heart Failure • Hypertension • Obesity

Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors (clinicaltrials.gov) - P3 | N=422 | Recruiting | Sponsor: University of Rochester NCORP Research Base | Trial completion date: Sep 2025 ➔ Dec 2025

Trial completion date • Breast Cancer • Fatigue • Hematological Malignancies • Oncology • Solid Tumor

Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors (clinicaltrials.gov) - P3 | N=422 | Recruiting | Sponsor: University of Rochester NCORP Research Base | Trial completion date: Mar 2025 ➔ Sep 2025 | Trial primary completion date: Oct 2024 ➔ Sep 2025

Trial completion date • Trial primary completion date • Breast Cancer • Fatigue • Oncology

Bupropion in Reducing Cancer Related Fatigue in Stage I-III Breast Cancer Survivors (clinicaltrials.gov) - P3 | N=422 | Recruiting | Sponsor: University of Rochester NCORP Research Base | Trial completion date: Mar 2024 ➔ Mar 2025 | Trial primary completion date: Oct 2023 ➔ Oct 2024

Trial completion date • Trial primary completion date • Breast Cancer • Fatigue • Oncology • Solid Tumor

Metformin as Adjunct Therapy in Depression-Obesity Comorbidity: Clinical and Genetic Evaluation (clinicaltrials.gov) - P=N/A | N=200 | Active, not recruiting | Sponsor: Riphah International University

New trial • CNS Disorders • Depression • Familial Hypercholesterolemia • Genetic Disorders • Mood Disorders • Obesity • Psychiatry

BUPRO-06-25: An open label, balanced, randomized, three treatment, three period, three sequence, single dose, crossover study to assess the effect of food and effect of apple sauce on bioavailability of the Test nproduct (Bupropion Hydrochloride Extended Release Capsules 150 mg, manufactured by Sun Pharmaceutical Industries Limited, India) in healthy, adult, human subjects. (clinicaltrialsregister.eu) - P1 | N=72 | Not yet recruiting | Sponsor: Sun Pharmaceutical Industries Limited

New P1 trial • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

BUPRO-05-25: An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose crossover, bioavailability study comparing Bupropion Hydrochloride Extended Release Capsules 150 mg, Manufactured by Sun Pharmaceutical Industries Limited, India with WELLBUTRIN XL (Bupropion hydrochloride) extended release tablets 300 mg, Distributed by: Bausch Health US, LLC Bridgewater, NJ... (clinicaltrialsregister.eu) - P1 | N=72 | Not yet recruiting | Sponsor: Sun Pharmaceutical Industries Limited

New P1 trial • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Bupropion Interference with DaT Scan Accuracy: A Case of a False Positive Diagnosis of Parkinson’s Disease (AAN 2026) - "Results A 47-year-old man with major depressive disorder, treated with bupropion XL 450 mg daily, and mild bilateral hand action tremors since his youth, presented with new onset left hand and leg rest tremor. Conclusions A medication hold duration of five elimination half-lives (8 days) may be insufficient for avoiding bupropion interference in the accuracy of Ioflupane 123I SPECT scans. A longer hold duration should be considered to ensure an accurate finding of dopamine deficiency."

Clinical • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Movement Disorders • Parkinson's Disease

Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE) (clinicaltrials.gov) - P4 | N=8600 | Active, not recruiting | Sponsor: Currax Pharmaceuticals | Recruiting ➔ Active, not recruiting

Adverse events • Enrollment closed • Cardiovascular • Genetic Disorders • Obesity

Development of a MHBC Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: Yale University | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Obesity • Tobacco Cessation

Successful Treatment of Severe Bupropion Overdose Using Plasma Exchange and Lipid Emulsion Therapy (SCCM 2026) - "Introduction: The use of ECMO, lipid emulsion therapy (LE), and plasma exchange (PLEX) for massive bupropion XL (BUP) overdose has been described in case reports and series focusing on outcomes. Assuming urine concentrations decrease proportionally to serum, this would exceed expected elimination without extracorporeal clearance. This is the first reported case demonstrating LE paired with PLEX can markedly reduce BUP half-life and lead to rapid hemodynamic and neurologic recovery."

Cardiovascular • Cough • Hypotension • Respiratory Diseases

Successful Management of Bupropion Extended-release Overdose With Early Veno-arterial Extracorporeal Membrane Oxygenation (VA-ECMO): A Case Report (ATS 2026) - No abstract available

Case report • Clinical

Pharmacogenetic influence on bupropion bioactivation and clinical outcomes in major depressive disorder. (PubMed, J Pharmacol Exp Ther) - "This was a preplanned secondary analysis of a prospective, 24-week, randomized, double-blind, crossover trial which compared pharmacokinetics and antidepressant effects across brand and 3 generic bupropion XL 300 mg drug products in 70 participants with major depressive disorder in remission, who were genotyped for CYP2B6 and CYP2C19 polymorphisms. CYP2C19 polymorphisms had a small and clinically unimportant influence on bupropion minor metabolites and secondary metabolism and no effect on depression or side effect scores. These results may have implications for genetic testing in bupropion pharmacotherapy of major depressive disorder."

Biomarker • Clinical • Clinical data • Journal • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry • CYP2C19

RNA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipolar Depression (EDIT-ANDRE) (clinicaltrials.gov) - P4 | N=120 | Recruiting | Sponsor: Mayo Clinic | Not yet recruiting ➔ Recruiting

Biomarker • Enrollment open • Bipolar Disorder • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

New-Onset Tic Disorder Associated With Bupropion XL: A Rare Case. (PubMed, Cureus) - "Tics are sudden, rapid, non-rhythmic movements or vocalizations. The tics subsided completely upon discontinuation of bupropion and initiation of low-dose risperidone. This case highlights a rare but clinically significant adverse effect of bupropion, underscoring the need for clinical vigilance when prescribing this agent."

Journal • CNS Disorders • Depression • Movement Disorders • Psychiatry • Tic Disorders • Tobacco Cessation • Tourette Syndrome

A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients (clinicaltrials.gov) - P1/2 | N=64 | Not yet recruiting | Sponsor: Yale University

New P1/2 trial • Genetic Disorders • Obesity • Tobacco Cessation

TTOP: Tobacco Treatment Optimization and Preferences During Concurrent Cancer Treatment (clinicaltrials.gov) - P2 | N=126 | Completed | Sponsor: Joseph Valentino, MD | Active, not recruiting ➔ Completed

Trial completion • Oncology • Tobacco Cessation